锐客网

  1. 首页 > 生活杂烩 > 健康 > >

精准医学|樊嘉：精准医学时代肝细胞癌的系统治疗｜专家视角( 七 )


［22］KELLEY RK, VERSLYPE C, COHN AL, et al. Cabozantinib in hepatocellular carcinoma: Results of a phase 2 placebo-controlled randomized discontinuation study［J］. Ann Oncol, 2017, 28(3): 528-534.
［23］ABOU-ALFA GK, MEYER T, CHENG AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma［J］. N Engl J Med, 2018, 379(1): 54-63.
［24］HEINRICH S, CASTVEN D, GALLE PR, et al. Translational considerations to improve response and overcome therapy resistance in immunotherapy for hepatocellular carcinoma［J］. Cancers (Basel), 2020, 12(9): e2495.
［25］SANGRO B, GOMEZ-MARTIN C, de la MATA M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C［J］. J Hepatol, 2013, 59(1): 81-88.
［26］ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial［J］. Lancet Oncol, 2018, 19(7): 940-952.
［27］EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial［J］. Lancet, 2017, 389(10088): 2492-2502.
［28］FINN RS, RYOO BY, MERLE P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial［J］. J Clin Oncol, 2020, 38(3): 193-202.
［29］REBOUISSOU S, LA BELLA T, REKIK S, et al. Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro［J］. Clin Cancer Res, 2017, 23(15): 4364-4375.
［30］HU Z, OTT PA, WU CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer［J］. Nat Rev Immunol, 2018, 18(3): 168-182.
［31］NEELAPU SS, LOCKE FL, GO WY. CAR T-cell therapy in large B-cell lymphoma［J］. N Engl J Med, 2018, 378(11): 1065.
［32］NEELAPU SS, TUMMALA S, KEBRIAEI P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities［J］. Nat Rev Clin Oncol, 2018, 15(1): 47-62.
［33］PARK R, ESHRAT F, AL-JUMAYLI M, et al. Immuno-oncotherapeutic approaches in advanced hepatocellular carcinoma［J］. Vaccines (Basel), 2020, 8(3): e447.
［34］PENG L, BIAN XW, LI DK, et al. Large-scale RNA-Seq transcriptome analysis of 4043 cancers and 548 normal tissue controls across 12 TCGA cancer types［J］. Sci Rep, 2015, 5: 13413.
［35］FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］. N Engl J Med, 2020, 382(20): 1894-1905.
［36］FINN RS, IKEDA M, ZHU AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma［J］. J Clin Oncol, 2020, 38(26): 2960-2970.
［37］KELLEY RK, W OLIVER J, HAZRA S, et al. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design［J］. Future Oncol, 2020, 16(21): 1525-1536.
［38］GUARDASCIONE M, TOFFOLI G. Immune checkpoint inhibitors as monotherapy or within a combinatorial strategy in advanced hepatocellular carcinoma［J］. Int J Mol Sci, 2020, 21(17): e6302.
［39］FENG GS, HANLEY KL, LIANG Y, et al. Improving the efficacy of liver cancer immunotherapy: The power of combined preclinical and clinical studies［J］.Hepatology, 2020. ［Online ahead of print］
［40］ZHU XD, LI KS, SUN HC. Adjuvant therapies after curative treatments for hepatocellular carcincma: Current status and prospects［J］.Genes Dis,2020,7(3): 359-369.
［41］CANALE M, ULIVI P, FOSCHI FG, et al. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma［J］. Crit Rev Oncol Hematol, 2018, 129: 44-53.
［42］ZHU HB, ZENG PH, GAO WH, et al. Discussion on the treatment of hepatocarcinoma with the multi-disciplinary integrated treatment team model combining traditional Chinese medicine and western medicine［J］. Guid J Tradit Chin Med Pharmacol, 2019, 25(22): 21-24, 31. (in Chinese)

推荐阅读


上一篇：达卡巴嗪|达卡巴嗪的溶媒及输注时间

下一篇：哈尔滨市疾控中心|哈尔滨市疾控中心发布！在外就餐和手部卫生注意事项！